NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis. 7. Juni 2015 Kurbacher, C.M., Fietz, T., Diel, I.J., Egert, M., Hurtz, H.-J., Lück, A., Weide, R., Salat, C., Wolff, T., Zaiss, M., Klare, P., Losem, C., Illmer, T., Weißenborn, G., Steffens, C.-C., Schulze, M., Tesch, H., Oskay-Oezcelik, G., Teichmann, B., Harde, J., Scheuerlein, R.W., 2015. Oncol Res Treat 38, 221–229. doi:10.1159/000381631 Abstract Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: subgroup analysis of the non-interventional study NADIR. Kurbacher, C., Fietz, T., Salat, C., Zaiss, M., Gazawi, N., Steffens, C.-C., Egert, M., Graffunder, G., Papke, J., Weißenborn, G., Brückner, U., Illmer, T., Jungberg,… Weiterlesen Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study. Marschner, N., Arnold, D., Engel, E., Hutzschenreuter, U., Rauh, J., Freier, W., Hartmann, H., Frank, M., Jänicke, M., 2015. Clinical Epidemiology 7, 295–303. doi:10.2147/CLEP.S73857… Weiterlesen